Document Classification

Section Type: METHODS

Text: Untreated patients aged 14-59 years with acute myeloid leukaemia were randomly assigned (by a computer-generated allocation schedule without stratification) to receive one of three induction regimens in a 1:1:1 ratio : homoharringtonine 2 mg/m (2) per day on days 1-7, cytarabine 100 mg/m (2) per day on days 1-7, and aclarubicin 20 mg/day on days 1-7 (HAA) ; homoharringtonine 2 mg/m (2) per day on days 1-7, cytarabine 100 mg/m (2) per day on days 1-7, and daunorubicin 40 mg/m (2) per day on days 1-3 (HAD) ; or daunorubicin 40-45 mg/m (2) per day on days 1-3 and cytarabine 100 mg/m (2) per day on days 1-7 (DA).